Mobile website
Expert Forum
Induction of committed differentiation and target immunotherapy of patients with hematopoietic malignancy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In addition to the conventional therapeutic strategies, biotherapy also plays an important part in the treatment of hematopoietic malignancy (HM). According to the differentiation disorders of leukemia cells, HM should be treated by different differentiation inducers, which may induce them to differentiate into granulocytes, monocytes or DCs. Secondly, based on the key disease-associated genes, proteins, and cell surface antigen molecules in the pathogenesis of HM, new anti-HM drugs such as target antibody can be designed. Thirdly, based on the relationship of abnormalities of DNA methylation, chromosomes histone acetylation and histone deacetylation with the differentiation disorder of leukemia cells, some researchers studied the epigenetic modification of leukemia-associated genes and the therapeutic effects of anti-HM drugs regulating DNA methylation and histone acetylation. Last, tumor antigen or peptide specific tumor vaccines, cytokine/receptors-mediated target therapy, and partially-targeted cell vector-based therapy also have potential clinical applications. In conclusion, the differentiation inducers, key genes and molecule-targeted drugs and other target therapy agents all provide new ways for the treatment of HM; these agents used alone or in combination with other therapies will greatly enhance the treatment outcomes of HM.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 30771103, No. 30810444), the National “Eleventh five-years plan” Key Project for Development of New Drugs (No. 2009ZX09503-010), and the Key Scientific Foundation of Shandong Province (No. 2007GG2002023)
Clc Number:
